tacrolimus modified release + tacrolimus injection

This is a combination regimen of **tacrolimus in its modified (extended or prolonged) release oral formulation, plus tacrolimus administered by injection (intravenous or intramuscular)**. Tacrolimus is an **immunosuppressant** used primarily to prevent organ transplant rejection. The modified release oral tacrolimus (e.g., marketed as Advagraf, Astagraf XL) offers once-daily dosing and improves patient adherence, while the injectable form is typically used around the time of transplantation or when oral absorption may be compromised. Both forms share the same mechanism of action: they inhibit **calcineurin**, resulting in the suppression of T-cell activation and the subsequent immune response. Tacrolimus is primarily indicated for prophylaxis of organ rejection in kidney, liver, and heart transplantation, and it is frequently combined with mycophenolate mofetil and corticosteroids[1][3][5][7].

Brand names

AdvagrafAstagraf XLPrograf

Other names

tacrolimus extended-release + tacrolimus (injection)tacrolimus prolonged-release + tacrolimus (injection)FK506 extended-release + FK506 injection